Get the Stockscreener App
3.68
1.38%
0.05
After Hours:
3.68
Ardelyx Inc stock is traded at $3.68, with a volume of 4.96M.
It is up +1.38% in the last 24 hours and down -7.30% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$3.63
Open:
$3.69
24h Volume:
4.96M
Relative Volume:
0.90
Market Cap:
$894.81M
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-11.74
EPS:
-0.3134
Net Cash Flow:
$-63.80M
1W Performance:
+3.66%
1M Performance:
-7.30%
6M Performance:
-20.69%
1Y Performance:
-41.12%
1-Day Range:
$3.55
$3.72
1-Week Range:
$3.49
$3.72
52-Week Range:
$3.21
$8.06
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
3.68 | 894.81M | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Director David Mott Acquires 200,000 Shares of Ardelyx Inc (ARDX) - GuruFocus
Ardelyx Stockholders Approve Equity Plan Amendment - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - Bluefield Daily Telegraph
ARDX Gains Attention with HC Wainwright & Co. Buy Rating | ARDX Stock News - GuruFocus
H.C. Wainwright assumes coverage on Ardelyx stock with buy rating By Investing.com - Investing.com India
Ardelyx (ARDX) Receives Positive Coverage with Buy Rating and $10 Target | ARDX Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. ... - Bluefield Daily Telegraph
Hedge Fund and Insider Trading News: Paul Tudor Jones, Divya Nettimi, Scott Bessent, Marshall Wace, Warren Buffett, Rokos Capital Management, Ardelyx Inc (ARDX), Ralph Lauren Corp (RL), and More - Insider Monkey
Ardelyx director David Mott acquires $737,260 in stock By Investing.com - Investing.com South Africa
Ardelyx director David Mott acquires $737,260 in stock - Investing.com
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Ardelyx is hiring: Director, Marketing in New York at Ardelyx Job - Mediabistro
Transcript : Ardelyx, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - MarketScreener
Ardelyx at Jefferies Conference: Strategic Growth and Market Challenges By Investing.com - Investing.com India
Ardelyx at Jefferies Conference: Strategic Growth and Market Challenges - Investing.com
Ardelyx is hiring: Director, Marketing in Waltham at Ardelyx Job - Mediabistro
Ardelyx reshuffles leadership, adds new HR chief By Investing.com - Investing.com South Africa
Ardelyx appoints Mike Kelliher Chief Business Officer - TipRanks
Ardelyx Promotes Mike Kelliher to Chief Business Officer - marketscreener.com
Ardelyx reshuffles leadership, adds new HR chief - Investing.com Australia
Ardelyx (ARDX) Appoints New Leadership in Strategic Roles | ARDX Stock News - GuruFocus
Ardelyx Appoints Mike Kelliher Chief Business Officer - marketscreener.com
Ardelyx Appoints Mike Kelliher Chief Business Officer and James - GuruFocus
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - The Manila Times
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer | ARDX Stock News - GuruFocus
Ardelyx Expands Leadership: Strategic Promotion and Key Executive Hire Signal Growth Push - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.
Ardelyx, Inc. (ARDX) Stock Analysis: Investors Eye a Promising 167.99% Upside Potential - DirectorsTalk Interviews
Learn to Evaluate (ARDX) using the Charts - news.stocktradersdaily.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
Deutsche Bank AG Boosts Position in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx chief medical officer sells shares worth $26,206 By Investing.com - Investing.com South Africa
Ardelyx CFO sells $29,459 in stock By Investing.com - Investing.com South Africa
Ardelyx chief medical officer sells shares worth $26,206 - Investing.com Australia
Ardelyx officer Mike Kelliher sells $59,270 in stock By Investing.com - Investing.com South Africa
Ardelyx CFO sells $29,459 in stock - Investing.com Australia
Ardelyx officer Mike Kelliher sells $59,270 in stock - Investing.com Australia
Ardelyx Executives Sell Shares to Cover Taxes - TradingView
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOTT DAVID M | Director |
Jun 09 '25 |
Buy |
3.69 |
200,000 |
737,260 |
2,696,871 |
| Williams Laura A | Chief Medical Officer |
May 20 '25 |
Sale |
4.08 |
6,421 |
26,207 |
402,583 |
| Renz Justin A | Chief Financial Officer |
May 20 '25 |
Sale |
4.08 |
7,218 |
29,460 |
416,089 |
| RAAB MICHAEL | President & CEO |
May 20 '25 |
Sale |
4.08 |
46,817 |
191,079 |
1,547,937 |
| Kelliher Mike | See Remarks |
May 20 '25 |
Sale |
4.08 |
14,522 |
59,270 |
282,158 |
| GRAMMER ELIZABETH A | See Remarks |
May 20 '25 |
Sale |
4.08 |
5,992 |
24,456 |
311,731 |
| Foster Eric Duane | Chief Commercial Officer |
May 20 '25 |
Sale |
4.08 |
2,507 |
10,232 |
316,806 |
| MOTT DAVID M | Director |
May 15 '25 |
Buy |
3.29 |
100,000 |
329,120 |
2,496,871 |
| MOTT DAVID M | Director |
May 02 '25 |
Buy |
4.22 |
381,377 |
1,610,936 |
2,396,871 |
| RAAB MICHAEL | President & CEO |
May 02 '25 |
Option Exercise |
0.99 |
20,833 |
20,625 |
1,636,420 |
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):